NZ704012A - Opioid formulations - Google Patents

Opioid formulations

Info

Publication number
NZ704012A
NZ704012A NZ704012A NZ70401213A NZ704012A NZ 704012 A NZ704012 A NZ 704012A NZ 704012 A NZ704012 A NZ 704012A NZ 70401213 A NZ70401213 A NZ 70401213A NZ 704012 A NZ704012 A NZ 704012A
Authority
NZ
New Zealand
Prior art keywords
buprenorphine
opioid formulations
methods
depot
opioid
Prior art date
Application number
NZ704012A
Other languages
English (en)
Inventor
Fredrik Tiberg
Ian Harwigsson
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ704012(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Priority to NZ735248A priority Critical patent/NZ735248A/en
Priority claimed from PCT/EP2013/065855 external-priority patent/WO2014016428A1/en
Publication of NZ704012A publication Critical patent/NZ704012A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
NZ704012A 2012-07-26 2013-07-26 Opioid formulations NZ704012A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ735248A NZ735248A (en) 2012-07-26 2013-07-26 Opioid formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28
PCT/EP2013/065855 WO2014016428A1 (en) 2012-07-26 2013-07-26 Opioid formulations

Publications (1)

Publication Number Publication Date
NZ704012A true NZ704012A (en) 2017-09-29

Family

ID=53487482

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ704012A NZ704012A (en) 2012-07-26 2013-07-26 Opioid formulations
NZ735248A NZ735248A (en) 2012-07-26 2013-07-26 Opioid formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ735248A NZ735248A (en) 2012-07-26 2013-07-26 Opioid formulations

Country Status (20)

Country Link
US (4) US12161640B2 (https=)
JP (1) JP6417327B2 (https=)
CN (1) CN109010255B (https=)
AU (3) AU2016244271B2 (https=)
CL (1) CL2015000197A1 (https=)
CY (1) CY1124016T1 (https=)
DK (1) DK2877155T3 (https=)
EA (1) EA034855B1 (https=)
ES (1) ES2837803T3 (https=)
HK (1) HK1221636A1 (https=)
HR (1) HRP20210068T1 (https=)
HU (1) HUE053273T2 (https=)
IL (3) IL296882A (https=)
LT (1) LT2877155T (https=)
MX (2) MX387722B (https=)
MY (1) MY189481A (https=)
NZ (2) NZ704012A (https=)
PE (1) PE20150672A1 (https=)
PT (1) PT2877155T (https=)
SG (2) SG10201703964TA (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ704012A (en) 2012-07-26 2017-09-29 Camurus Ab Opioid formulations
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
WO2019071245A1 (en) * 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
WO2019136490A1 (en) 2018-01-08 2019-07-11 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
EP3793536A1 (en) 2018-05-12 2021-03-24 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
US12303619B2 (en) 2018-08-28 2025-05-20 Foundry Therapeutics, Inc. Polymer implants
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
WO2022175974A1 (en) * 2021-02-18 2022-08-25 Navin Saxena Research And Technology Private Limited Non-aqueous injectable composition for sustained release of buprenorphine and use thereof
CN117999079A (zh) * 2021-08-20 2024-05-07 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
HU221308B1 (en) 1992-10-26 2002-09-28 Sanol Arznei Schwarz Gmbh Process for producing microcapsules
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
JP4137179B2 (ja) 1994-03-30 2008-08-20 ジーエス ディベロップメント エービー 生物付着性物質としての脂肪酸エステルの使用
ATE317690T1 (de) 1994-04-08 2006-03-15 Qlt Usa Inc Flüssige zusammensetzungen zur arzneistoffabgabe
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
ATE223202T1 (de) 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
FR2726762B1 (fr) 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
WO1997013528A1 (en) 1995-10-12 1997-04-17 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SE9802528D0 (sv) 1998-07-13 1998-07-13 Gs Dev Ab Bone tissue restoring composition
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
JP3952617B2 (ja) 1998-12-11 2007-08-01 株式会社日立製作所 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20030003144A1 (en) 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20040022820A1 (en) 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
CA2487577C (en) 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
RU2005134364A (ru) 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
WO2005117830A1 (en) 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
PL1682091T3 (pl) 2003-11-07 2017-09-29 Camurus Ab Kompozycje lipidów i kationowych peptydów
WO2005110360A2 (en) 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
GB0412530D0 (en) 2004-06-04 2004-07-07 Camurus Ab Formulation
JP5144277B2 (ja) * 2005-01-14 2013-02-13 カムルス エービー 局所用生体付着性製剤
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
US9757461B2 (en) 2005-01-14 2017-09-12 Camurus Ab GnRH analogue formulations
KR101245022B1 (ko) 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US9226918B2 (en) 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
US8975270B2 (en) 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
EP2611445B1 (en) 2010-09-03 2018-08-15 Zoetis Belgium S.A. High dose buprenorphine compositions and use as analgesic
EP4427814A3 (en) 2011-05-25 2024-11-20 Camurus AB Controlled release peptide formulations
US9585959B2 (en) 2011-12-05 2017-03-07 Camurus Ab Robust controlled-release formulations
NZ704012A (en) 2012-07-26 2017-09-29 Camurus Ab Opioid formulations
EP3791861A1 (en) 2012-07-26 2021-03-17 Camurus AB Opioid formulations
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
US11920160B2 (en) 2013-02-22 2024-03-05 Cedars-Sinai Medical Center Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
CN105358129A (zh) 2013-03-15 2016-02-24 赫伦治疗有限公司 聚原酸酯和质子惰性溶剂的组合物
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
JP6476658B2 (ja) 2013-09-11 2019-03-06 ソニー株式会社 画像処理装置および方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
US10471052B2 (en) 2015-02-19 2019-11-12 Mymd Pharmaceuticals, Inc. Method of treating addictions to opioids
GB201516554D0 (en) 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
RU2729274C2 (ru) 2015-10-28 2020-08-05 Хальдор Топсеэ А/С Дегидрирование этилбензола с получением стирола
EP3863712A4 (en) 2018-10-11 2022-07-20 Indivior UK Limited BUPRENORPHINE USED TO TREAT RESPIRATORY DEPRESSION

Also Published As

Publication number Publication date
EA201590202A1 (ru) 2015-07-30
DK2877155T3 (da) 2021-01-18
MX361873B (es) 2018-12-18
CY1124016T1 (el) 2022-05-27
US12161640B2 (en) 2024-12-10
AU2019200982B2 (en) 2019-07-18
ES2837803T3 (es) 2021-07-01
JP6417327B2 (ja) 2018-11-07
US20240131021A1 (en) 2024-04-25
MX2015001033A (es) 2015-04-09
HK1205948A1 (en) 2015-12-31
CL2015000197A1 (es) 2015-11-13
JP2015522649A (ja) 2015-08-06
MX387722B (es) 2025-03-18
AU2016244271A1 (en) 2016-10-27
CN109010255B (zh) 2022-10-21
HK1221636A1 (en) 2017-06-09
AU2016244271B2 (en) 2018-01-18
HRP20210068T1 (hr) 2021-03-05
BR112015001548A2 (pt) 2017-07-04
HUE053273T2 (hu) 2021-06-28
NZ735248A (en) 2018-10-26
IL236762A0 (en) 2015-03-31
US20240226091A9 (en) 2024-07-11
US20260097031A1 (en) 2026-04-09
PT2877155T (pt) 2020-12-18
EA034855B1 (ru) 2020-03-30
LT2877155T (lt) 2021-02-25
SG11201500554XA (en) 2015-02-27
US20240075024A1 (en) 2024-03-07
PE20150672A1 (es) 2015-05-21
AU2017279657B2 (en) 2018-11-15
US12318379B2 (en) 2025-06-03
CN109010255A (zh) 2018-12-18
IL289157A (en) 2022-02-01
MY189481A (en) 2022-02-16
US20250049783A1 (en) 2025-02-13
IL296882A (en) 2022-12-01
AU2019200982A1 (en) 2019-02-28
AU2017279657A1 (en) 2018-01-18
SG10201703964TA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
NZ704012A (en) Opioid formulations
CO7190238A2 (es) Formulaciones de opioides
MX2015007710A (es) Indanilcarboxamidas difluorometil-nicotinicas.
NZ719079A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
TN2014000001A1 (en) A new therapeutical composition containing apomorphine as active ingredient
NZ590650A (en) Buprenorphine analogs
MY183540A (en) Injectable buprenorphine formulation
PH12015501982A1 (en) Pharmaceutical compositions comprising everolimus
IN2014DN01619A (https=)
MY196998A (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
MX357704B (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
IN2015DN01329A (https=)
MX359955B (es) Formulación de aroma y fragancia (iii).
MX2015004312A (es) Formulacion de aroma y fragancia (i).
PH12013500027A1 (en) Therapeutic agents 976
MX2015004316A (es) Formulacion de aroma y fragancia (iv).
MX360531B (es) Formulación de aroma y fragancia (ii).
MY166773A (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
HK1239562A1 (en) Injectable buprenorphine formulation
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
UA61103U (ru) Фармацевтическая композиция для лечения множественно-резистентных форм туберкулеза
UA69383U (ru) Гель для обработки рук с противобактериальным действием

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUL 2019 BY COMPUTER PACKAGES INC

Effective date: 20180703

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUL 2020 BY COMPUTER PACKAGES INC

Effective date: 20190702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUL 2021 BY COMPUTER PACKAGES INC

Effective date: 20200701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUL 2022 BY COMPUTER PACKAGES INC

Effective date: 20210630

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUL 2023 BY COMPUTER PACKAGES INC

Effective date: 20220630

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUL 2024 BY COMPUTER PACKAGES INC

Effective date: 20230630

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUL 2025 BY COMPUTER PACKAGES INC

Effective date: 20240630

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUL 2026 BY COMPUTER PACKAGES INC

Effective date: 20250630